This article is more than 5 years old. Information may no longer be current.
Patients with psoriatic arthritis at slightly higher risk for CV disease
Click Here to Manage Email Alerts
Patients with psoriatic arthritis had a slightly higher risk for developing cardiovascular disease or a major adverse cardiac event compared to individuals without either psoriatic arthritis or psoriasis, according to the results of a recently published study.
Researchers identified 7,982 patients with psoriatic arthritis (PsA) and 74,583 individuals without PsA in a cardiovascular disease (CVD) cohort. They also identified 8,454 patients with PsA and 82,308 individuals without PsA in a major adverse cardiac event (MACE) cohort from the United Kingdom Clinical Practice Research Datalink (CPRD). The CPRD is a longitudinal, population-based electronic database of medical records for about 10 million people. Patients who had at least 1 year of medical data available were included for analysis.
Kaplan-Meier analysis revealed the incidence rate (IR) for CVD was 12.8 per 1,000 person-years for patients with PsA compared to 9.6 per 1,000 person-years in participants without PsA, which yielded an IR ratio of 1.33. The risk rates were higher for men and increased with age in both participants with and without PsA. However, investigators found higher rates in patients with PsA when stratified by age in all age groups.
Patients with PsA who received medication to treat PsA had an IR of 15.4 per 1,000 patient-years for developing CVD compared to an IR of 12.1 per 1,000 person-years in participants without PsA, and the rates were highest among patients with PsA who received corticosteroids.
The IR for incident MACE was 4.6 per 1,000 person-years for patients with PsA compared to 3.5 per 1,000 person-years for participants without PsA, resulting in an IR ratio of 1.30. As with CVD risk, the rates were higher for men in both cohorts, increased with age. Researchers also found higher rates for patients with PsA who received medications for PsA (IR 5.7 vs. 4.5 per 1,000 person-years). – by Shirley Pulawski
Disclosures: The researchers report the study was funded by Celgene. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts